Special Issue "SGLT2 Inhibitors: Emerging "Magic Bullets" Beyond Glycemic Control"
Deadline for manuscript submissions: 31 July 2021.
Interests: cardiovascular G protein-coupled receptors (GPCRs); heart failure; autonomic control of the circulation; adrenal physiology and pharmacology; adrenergic receptors; angiotensin receptors; signal transduction; gene therapy; aldosterone pharmacology; GPCR-Kinases; arrestins
Originally developed for restoring euglycemia in diabetes mellitus, SGLT2 inhibitors (SGLT2i’s) are increasingly being demonstrated to exert beneficial effects in patients, extending beyond blood glucose regulation. For instance, they reduce cardiovascular disease mortality, ameliorate kidney disease progression, lower blood pressure, and confer weight loss, even in non-diabetics or in people with end-stage chronic kidney disease. Therefore, a lot of information regarding the physiological effects and pharmacological mechanisms of SGLT2i`s remains to be obtained, necessitating more research to fully grasp their therapeutic potential.
On these grounds, this Special Issue of the International Journal of Molecular Sciences is focused on studies that explore the biological and pharmacological effects of SGLT2i`s in human physiology and disease. Investigations with a solid basic/molecular research foundation and/or translational potential are of particular interest, including papers exploring novel molecular and cellular mechanisms underlying the effects of these drugs, as well as pre-clinical investigations testing novel hypotheses that advance the molecular and clinical pharmacology of SGLT2 inhibitors. Original investigations, review articles, and short communications will all be considered. Purely clinical investigations are not suitable but clinical submissions with at least some component of molecular studies are quite welcome.
Suggested disease areas/topics to be covered include (but are by no means limited to) the following:
- cell biology;
- signal transduction;
- autonomic nervous system;
- atherosclerosis/lipid disorders;
- cognitive dysfunction/neurodegeneration and other central nervous system (CNS) disorders;
- heart failure and cardiac arrhythmias;
- metabolic syndrome/diabetes mellitus;
- stem cell biology/physiology;
- inflammatory and/or autoimmune diseases and pain;
- cardiovascular endocrinology (e.g., adrenal gland and neuronal control of the circulation);
- end-organ damage and sepsis;
- respiratory diseases;
- kidney disorders;
- vascular pathologies;
- obesity/adipose tissue biology;
- drug–drug interactions with other drug classes;
- adverse effects and toxicology;
- metabolism and pharmacokinetics in humans;
- effects in special populations (pediatric, geriatric, pregnancy, etc.);
- sex differences in drug action/response;
- cellular energetics/mitochondria;
- nuclear biology/DNA damage;
- oxidative stress.
Prof. Dr. Anastasios Lymperopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- glucose reduction
- metabolic disorders
- heart failure
- cardiovascular disease
- signal transduction
- kidney disease
- adverse effects